New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC. (8th May 2023)

• Record Type: Journal Article
• Authors: Rosar, Florian; Maus, Stephan; Schaefer-Schuler, Andrea; Burgard, Caroline; Khreish, Fadi; Ezziddin, Samer
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 5(2023)
• Page Start: 433
• Page End: 434
• Publication Date: 2023-05-08
• Subjects: prostate cancer -- PSMA -- radioligand therapy -- terbium-161; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004589
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177 Lu–prostate-specific membrane antigen (PSMA)–617 radioligand therapy (RLT) received 1 cycle of 161 Tb-PSMA RLT. This one administration of 6.5 GBq 161 Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence of the therapeutic potential of 161 Tb-PSMA RLT in metastatic castration-resistant prostate cancer, even in patients progressing after extensive 177 Lu-based RLT. 161 Tb-labeled PSMA ligands may thus offer a promising alternative to standard PSMA RLT.